Using MRI to measure drug action: caveats and new directions.

Using MRI to measure drug action: caveats and new directions.

Item
http://www.wikidata.org/entity/Q33618765
phMRI: methodological considerations for mitigating potential confounding factorsEffects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profileThe clinical implications of mouse models of enhanced anxiety.Use of functional imaging across clinical phases in CNS drug development.Efficacy markers in depression.Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia.Theranostic nanoparticles for cancer and cardiovascular applications.Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain.The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders.
P2860

Using MRI to measure drug action: caveats and new directions.

Item
http://www.wikidata.org/entity/Q33618765
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Using MRI to measure drug action: caveats and new directions.
@ast
Using MRI to measure drug action: caveats and new directions.
@en
type
label
Using MRI to measure drug action: caveats and new directions.
@ast
Using MRI to measure drug action: caveats and new directions.
@en
prefLabel
Using MRI to measure drug action: caveats and new directions.
@ast
Using MRI to measure drug action: caveats and new directions.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Using MRI to measure drug action: caveats and new directions
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698